Improving access and affordability could be transformative for public health, given that about 88% of Americans are metabolically unhealthy
The injections are generally well-tolerated
Manufacturers want broader access without giving up too much pricing power
Choosing the appropriate GLP-1 receptor agonist depends on your individual health profile, treatment goals, and lifestyle preferences
[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Research for effective treatments for Alzheimers disease (AD) is ongoing, but drug development faces challenges with a high failure rate